

CLINICAL PRIOR AUTHORIZATION FORM for NON-PDL DRUGS (form effective 7/10/2023)

Prior authorization guidelines Clinical Prior Authorization for Non-PDL Drugs and Quantity Limits/Daily Dose Limits are available on the DHS Pharmacy Services website at https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx.

Beneficiary name:		Beneficiary ID#:		Beneficiary DOB:		
•		,		Prescriber NPI:		
Prescriber name:		Prescr		IPI:		
Prescriber address (street/city/state/zip):						
Prescriber specialty:		Prescriber phone:		Prescriber fax:		
Office contact name:		Office contact phone:		Office contact fax:		
Billing provider name:		<u> </u>		Billing provider NPI:		
Billing provider address:						
CLINICAL INFORMATION						
Drug requested:						
Dosage form:	Strength:		Quantity:		Duration:	
Dose/directions:			Place of service:			
Doscrati ections.			Tide of service.			
Diagnosis (submit documentation):			Dx code (<u>required</u>):			
Complete all sections that apply to the beneficiary and this request.						
Check all that apply and submit documentation for each item.						
INITIAL requests						
The requested drug is being used for the treatment of a diagnosis that is indicated in the FDA-approved package labeling OR a medically accepted indication						
The beneficiary is of an appropriate age to receive the requested drug according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature						
☐ The prescribed dose and duration of therapy are consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature						
☐ The requested drug is prescribed by or in consultation with an appropriate specialist						
The beneficiary does <u>not</u> have a contraindication to the requested drug						
The beneficiary has baseline lab results as recommended in the FDA-approved package labeling						
The beneficiary tried and failed or has a contraindication or an intolerance to first-line therapy(ies), if applicable, according to						





consensus treatment guidelines					
The beneficiary has not failed a previous course or trial of the requested drug					
The beneficiary is <u>not</u> currently enrolled in a clinical trial for the requested drug					
RENEWAL requests					
☐The beneficiary has documentation of a positive clinical response to the requested drug					
The prescribed dose and duration of therapy are consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature					
☐The requested drug is prescribed by or in consultation with an appropriate specialist					
☐The beneficiary does not have a contraindication to the requested drug					
☐ The beneficiary has results of recent lab monitoring as recommended in the FDA-approved package labeling					
If applicable to the requested drug, the beneficiary is continuing treatment with the requested drug based on recent lab results as recommended in the FDA-approved package labeling					
PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS - PHARMACY DIVISION					
Prescriber Signature:	Date:				

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.